Since the introduction of the original prontosil by Domagk1 as a therapeutic agent against hemolytic streptococci in mice, its two derivatives prontosil soluble and sulfanilamide have been extensively used against a variety of infections in man.
Experimental evidence by Rosenthal,2 by Cooper, Gross and Mellon3 and by Cooper and Gross4 show that sulfanilamide has distinctly therapeutic properties in rats and mice infected with the type III pneumococcus. Heintzelman, Hadley and Mellon5 reported a small series of nineteen cases of type III pneumococcus lobar pneumonia, which carries a high mortality in the Pittsburgh area. Of nine patients who received sulfanilamide, seven lived and two died, while of the remaining untreated patients eight died and two recovered. At the Meadowbrook Hospital6 a crisis was induced by sulfanilamide twenty-four hours after onset of a type III lobar pneumonia, which was contrary to our experience with the disease
MILLETT J. THE INTRATHECAL USE OF PRONTOSIL SOLUBLE: REPORT OF A CASE OF TYPE III PNEUMOCOCCUS MENINGITIS AND SEPTICEMIA TREATED WITH PRONTOSIL SOLUBLE, WITH COMPLETE AUTOPSY REPORT. JAMA. 1937;109(26):2138–2139. doi:10.1001/jama.1937.02780520028007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: